In particular, studies on GBM patients have shown that Phosphatase and Tensin homologue (PTEN)‐deficient cells, such as one of the primary lines tested (BT 517), which showed higher levels of PARP1 after Cisplatin treatment, could benefit from combining PARP inhibitors with standard treatments [43]. Here, PARP1 is linked to glioblastoma.